Compare Emerson Electric Co. (EMR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Sanofi SA — how do they compare? Emerson Electric Co. trades at $136.74 (market cap $76.31B), while Sanofi SA trades at $43.7 (market cap $103.94B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.54%). Which is the better fit depends on your goals.
| EMR | SNY | |
|---|---|---|
Market Cap | $76.31B | $103.94B |
Sector | Industrials | Health |
52-Week High | $161.69 | $52.34 |
52-Week Low | $123.30 | $41.33 |
Enterprise Value | $88.58B | $120.43B |
Dividend Yield | 1.63% | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $136.11, showing modest daily gains amid a bearish technical signal. The company maintains solid fundamentals with a 13.35% net income margin and recent earnings beats, though valuation multiples like a P/E of 31.54 appear elevated. Analyst consensus is bullish with a $157.60 price target, but cash flow volatility and a high debt-to-asset ratio of 31.26% in 2025 pose concerns. Recent news highlights upcoming Q3 2026 earnings and growth in the Intelligent Devices segment.
EMR offers a balanced risk-reward profile; strong profitability and analyst support suggest upside, but technical weakness and financial leverage require caution. The stock's trajectory hinges on sustaining earnings momentum and managing debt, with key resistance near $137.
Sanofi (SNY) trades at $43.18, down 1.86% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 71.92% gross margins and 15.95% net income margin, supported by recent FDA approvals for Sarclisa and other pipeline developments. Cash flow remains positive at $49 million for 2025, though net cash flow has declined from previous years.
Investment outlook is mixed with analyst consensus leaning neutral (44% buy, 52% hold) amid regulatory scrutiny from EU antitrust probes. Key opportunities include Dupixent's growth and new drug approvals, while risks involve competition and patent expirations. The stock trades at reasonable valuations with P/E of 19.37 and P/B of 1.26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
